| Authors: |
Sousa LG; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., McGrail DJ; Lerner Research Institute, Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio., Lazar Neto F; Instituto do Cancer do Estado de Sao Paulo, Sao Paulo University, Sao Paulo, Brazil., Li K; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Marques-Piubelli ML; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ferri-Borgogno S; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dai H; Department of System Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mitani Y; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Spardy Burr N; Adenoid Cystic Carcinoma Research Foundation, Needham, Massachusetts., Cooper ZA; Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Kinneer K; Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Cortez MA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lin SY; Department of System Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bell D; Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, California., El Naggar A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Burks J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ferrarotto R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
